SCHOTT PHARMA AG & CO. KGAASCHOTT PHARMA AG & CO. KGAASCHOTT PHARMA AG & CO. KGAA

SCHOTT PHARMA AG & CO. KGAA

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.76 B‬EUR
1.00EUR
‪149.69 M‬EUR
‪957.09 M‬EUR
‪27.13 M‬
Beta (1Y)
0.78
Employees (FY)
‪4.69 K‬
Change (1Y)
+43 +0.93%
Revenue / Employee (1Y)
‪204.11 K‬EUR
Net income / Employee (1Y)
‪31.92 K‬EUR

About SCHOTT PHARMA AG & CO. KGAA


CEO
Andreas Reisse
Website
Headquarters
Mainz
Founded
2022
ISIN
DE000A3ENQ51
FIGI
BBG01JFK5NQ2
SCHOTT Pharma AG & Co. KgaA engages in the provision of designing drug containment and drug delivery solutions. It operates through the Drug Containment Solutions and Drug Delivery Systems segments. The Drug Containment Solutions segment focuses on the products from the Core category that currently make up the largest part of the DCS product portfolio. The Drug Delivery Systems segment includes products that are characterized by improved product functionality and belong to the HVS product portfolio. It offers a wide range of advanced drug containment solutions and delivery systems for inject able drugs that supply to the pharmaceutical and biotechnology industries. The company was founded on May 10, 2022 and is headquartered in Mainz, Germany.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 1SXP is 25.16 EUR — it has increased by 0.81% in the past 24 hours. Watch SCHOTT PHARMA AG & CO. KGAA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange SCHOTT PHARMA AG & CO. KGAA stocks are traded under the ticker 1SXP.
1SXP stock has risen by 3.91% compared to the previous week, the month change is a −6.87% fall, over the last year SCHOTT PHARMA AG & CO. KGAA has showed a −23.76% decrease.
We've gathered analysts' opinions on SCHOTT PHARMA AG & CO. KGAA future price: according to them, 1SXP price has a max estimate of 37.00 EUR and a min estimate of 24.70 EUR. Watch 1SXP chart and read a more detailed SCHOTT PHARMA AG & CO. KGAA stock forecast: see what analysts think of SCHOTT PHARMA AG & CO. KGAA and suggest that you do with its stocks.
1SXP reached its all-time high on Feb 29, 2024 with the price of 43.40 EUR, and its all-time low was 22.64 EUR and was reached on Dec 20, 2024. View more price dynamics on 1SXP chart.
See other stocks reaching their highest and lowest prices.
1SXP stock is 1.94% volatile and has beta coefficient of 0.78. Track SCHOTT PHARMA AG & CO. KGAA stock price on the chart and check out the list of the most volatile stocks — is SCHOTT PHARMA AG & CO. KGAA there?
Today SCHOTT PHARMA AG & CO. KGAA has the market capitalization of ‪3.76 B‬, it has increased by 3.60% over the last week.
Yes, you can track SCHOTT PHARMA AG & CO. KGAA financials in yearly and quarterly reports right on TradingView.
SCHOTT PHARMA AG & CO. KGAA is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
1SXP earnings for the last quarter are 0.23 EUR per share, whereas the estimation was 0.24 EUR resulting in a −5.75% surprise. The estimated earnings for the next quarter are 0.27 EUR per share. See more details about SCHOTT PHARMA AG & CO. KGAA earnings.
SCHOTT PHARMA AG & CO. KGAA revenue for the last quarter amounts to ‪237.00 M‬ EUR, despite the estimated figure of ‪238.13 M‬ EUR. In the next quarter, revenue is expected to reach ‪255.22 M‬ EUR.
1SXP net income for the last quarter is ‪33.97 M‬ EUR, while the quarter before that showed ‪46.26 M‬ EUR of net income which accounts for −26.56% change. Track more SCHOTT PHARMA AG & CO. KGAA financial stats to get the full picture.
Yes, 1SXP dividends are paid annually. The last dividend per share was 0.15 EUR. As of today, Dividend Yield (TTM)% is 0.60%. Tracking SCHOTT PHARMA AG & CO. KGAA dividends might help you take more informed decisions.
SCHOTT PHARMA AG & CO. KGAA dividend yield was 0.52% in 2024, and payout ratio reached 16.10%. The year before the numbers were 0.47% and 14.88% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 30, 2024, the company has ‪4.69 K‬ employees. See our rating of the largest employees — is SCHOTT PHARMA AG & CO. KGAA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SCHOTT PHARMA AG & CO. KGAA EBITDA is ‪238.35 M‬ EUR, and current EBITDA margin is 24.66%. See more stats in SCHOTT PHARMA AG & CO. KGAA financial statements.
Like other stocks, 1SXP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SCHOTT PHARMA AG & CO. KGAA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SCHOTT PHARMA AG & CO. KGAA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SCHOTT PHARMA AG & CO. KGAA stock shows the sell signal. See more of SCHOTT PHARMA AG & CO. KGAA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.